Swayamjeet Satapathy, Kunal R Chandekar, Nishikant A Damle
{"title":"Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer - Current State and Evolving Standards.","authors":"Swayamjeet Satapathy, Kunal R Chandekar, Nishikant A Damle","doi":"10.1016/j.cpet.2026.02.002","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate-specific membrane antigen (PSMA)-based theranostics represent a paradigm shift in the management of prostate cancer. PSMA-ligand PET/computed tomography has demonstrated superior diagnostic accuracy over conventional imaging across diverse clinical settings. Parallelly, robust phase 3 evidence has established [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy as a standard-of-care in metastatic castration-resistant prostate cancer (mCRPC), with significant improvements in survival end points and quality of life. Emerging data also support the safe and effective integration of [<sup>177</sup>Lu]Lu-PSMA-617 into earlier disease settings, including chemotherapy-naïve mCRPC and metastatic hormone-sensitive prostate cancer. Collectively, PSMA theranostics exemplify the crucial role of nuclear medicine in advancing precision care for prostate cancer.</p>","PeriodicalId":94168,"journal":{"name":"PET clinics","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PET clinics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.cpet.2026.02.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Prostate-specific membrane antigen (PSMA)-based theranostics represent a paradigm shift in the management of prostate cancer. PSMA-ligand PET/computed tomography has demonstrated superior diagnostic accuracy over conventional imaging across diverse clinical settings. Parallelly, robust phase 3 evidence has established [177Lu]Lu-PSMA-617 radioligand therapy as a standard-of-care in metastatic castration-resistant prostate cancer (mCRPC), with significant improvements in survival end points and quality of life. Emerging data also support the safe and effective integration of [177Lu]Lu-PSMA-617 into earlier disease settings, including chemotherapy-naïve mCRPC and metastatic hormone-sensitive prostate cancer. Collectively, PSMA theranostics exemplify the crucial role of nuclear medicine in advancing precision care for prostate cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
